Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar.
Fiche publication
Date publication
juillet 2022
Journal
Multiple sclerosis and related disorders
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DE SEZE Jérôme
Tous les auteurs :
Yamamura T, Weinshenker B, Yeaman MR, De Seze J, Patti F, Lobo P, von Büdingen HC, Kou X, Weber K, Greenberg B
Lien Pubmed
Résumé
This analysis evaluated long-term safety findings from the SAkuraSky and SAkuraStar studies with satralizumab in patients with neuromyelitis optica spectrum disorder (NMOSD).
Mots clés
All clinical trials, All demyelinating disease (CNS), Autoimmune diseases, Devic's syndrome, Neuromyelitis optica spectrum disorder, Patient safety
Référence
Mult Scler Relat Disord. 2022 07 5;66:104025